We corrected the sodium and restored normal mentation. This was not his first episode of hyponatremia. I met the patient when he was admitted to the ICU with mental status changes due to a sodium south of 120. +1 “ Nothing aggravates a nephrologist like a kidney that refuses to obey the math.” But I know have a loop diuretic success story in a patient with significant but stable outpatient hyponatremia. In the past, I have used loops in hospitalized patients with hyponatremia.
I have tried loops in hyponatremia on a number of occasions and though the math works, in my hands I have not found them to be effective. On the list of possible treatments are loop diuretics. Salt tablets can help, but often are inadequate to correct the hyponatremia. Urea has a good track record but I have not heard of it being used in the United States.
#Kayexalate potassium antidote free
The side effects reported for demeclocycline and lithium were such that we recommend not using them for any degree of hyponatraemia.įluid restriction, the cornerstone of therapy, is difficult to maintain and in severe cases is insufficient to correct hyponatremia (I’m thinking of patients with negative free water clearance). From the European Society of Intensive Care Medicine (ESICM), the European Society of Endocrinology (ESE) and the European Renal Association guidelines on hyponatremia: Demeclocycline, despite being a generic, is very expensive and not a good option. hospitalization, mortality, fractures, morbidity)? And if not, is Karyx planning on doing such a study? And if not, why not?įingers crossed but with a skeptic’s scowlīut my patients are still alive and they still have sodiums of 125.
I was wondering if you have any data that shows Auryxia reduces any patient oriented outcomes (e.g. I’m glad there is a new phosphate binder available for dialysis patients. Please feel free to reach out with any questions. If you are amendable, we will continue to reach out to share updates from Keryx and AURYXIA in the coming year that we hope will be useful for your readers and followers.
#Kayexalate potassium antidote full
The full press release is below and includes additional information.
In addition, Keryx has created the “Keryx Patient Plus” program to assist with patient accessibility to Auryxia.įor more information, please visit. Food and Drug Administration approved Auryxia in September 2014. Auryxia is the first and only absorbable-iron-based phosphate binder that is clinically proven to effectively control phosphate levels within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. Auryxia is approved for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In fact, Keryx just announced it has begun shipping AURYXIA™ (ferric citrate) tablets to wholesalers in the U.S. I’d like to periodically share updates from the company to keep you informed regarding its lead therapeutic product and commitment to patients on dialysis. My name is Julia XXXXX, and on behalf of Keryx Biopharmaceuticals, I’d like to introduce Keryx as a resource for you as you develop content for your blog, Precious Bodily Fluids, given your commitment to advancing understanding of renal diseases.
0 kommentar(er)
